The department of Translational Neurosciences presents a new study in Scientific Reports about a novel pharmacologic approach for selective inhibition of β-catenin via targeting a cryptic allosteric modulation site. Read the publication, Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer, to discover how the findings may provide a new perspective for therapeutic targeting of β-catenin.
Steven J. O’Day, M.D., and his colleagues at the Society Immunotherapy of Cancer: Fernanda I. Arnaldez, Charles G. Drake, Bernard A. Fox, Binqinq Fu, Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, and Paolo A. Ascierto, have published a new study in the Journal for ImmunoTherapy of Cancer, entitled: The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin 6 Signaling in COVID-19 –related Systemic Inflammatory Response.This publication examines how an immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in COVID-19 patients.
The Drug Discovery and Nanomedicine Laboratory (Yenugonda V and Waters A), along with Kesari S, and Allnutt AB, presents a review article in ACS Chemical Neuroscience highlighting the importance of Cdk5 activity and function in the brain and demonstrates how deregulation of Cdk5 can contribute to the development of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. Read the publication, Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease, to learn more. This article was also selected for ACS Editors’ Choice!
May 2020
Przemyslaw W. Twardowski, M.D., and his colleagues: Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., et al, have published a new study in the New England Journal of Medicine, entitled: Olaparib for Metastatic Castration-Resistant Prostate Cancer. This publication demonstrates the benefits of olaparib (PARP inhibitor) in patients with selected mutations of DNA repair system, a major significance for the treatment of prostate cancer. The results of this study are expected to provide a new, valuable treatment option for about 25% of patients with advanced prostate cancer who harbor DNA repair mutations.
The Department of Translational Molecular Medicine: Wang X, Bustos M, Zhang X, Ramos R, Tan C, Iila Y, Chang S, Salomon M, Tran K, Gentry R, Kravtsova-Ivantsiv Y, Kelly D, Mills G, Ciechanover A, Mao Y, Hoon D., in collaboration with A. Chiechanover (Nobel Laureate) Israel, D Kelly PNI, and Y. Mao Director U.of Fudan Neurosurgery and Clinical Programs Shanghai,published a new study inCancersentitled: Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors. This study examined the role of the ubiquitin E3-ligase RNF123 in modulating downstream NF-κB1 targets in glioblastoma (GB) tumor progression.
Romela Irene Ramos, MSc, laboratory manager of the Department of Translational Molecular Medicine, along with: Bustos M, Wu J, Jones P, Chang S, Kiyohara E, Tran K, Zhang X, Izraely S, Sagi-Assif O, Witz I, Davies M, Mills G, Kelly D, Irie R, Hoon D., in collaboration with MD Anderson, D. Kelly PNI, and Oregon Health Science U., have published a new study inMolecular Oncologyentitled: Upregulation of Cell Surface GD3 Ganglioside Phenotype is Associated with Human Melanoma Brain Metastasis. This study demonstrates cell surface ganglioside GD3 phenotype associates with melanoma brain tumor progression and treatment responses to Icaritin.
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.Chen D, Li G, Ji C, Lu Q, Qi Y, Tang C, Xiong J, Hu J, Yasar FBA, Zhang Y, Hoon DSB, Yao Y, Zhou L. J Immunother Cancer. 2020 May;8(1):e000154. doi: 10.1136/jitc-2019-000154. PMID: 32457124 Free article. This is a joint program on neuro immunotherapy with Directors of Neurosurgery Fudan U.
Congratulations to the Department of Translational Molecular Medicine, Department of Genomic Sequencing Center, Department of Immuno-Oncology and Clinical Research and The Pacific Neuroscience Institute, on your publication in Cancers, entitled: Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis. Matias A. Bustos, Kevin D. Tran, Negin Rahimzadeh, Rebecca Gross, Selena Y. Lin, Yoshiaki Shoji, Tomohiro Murakami, Christine L. Boley, Linh T. Tran, Hunter Cole, Daniel F. Kelly, Steven O’Day, and Dave S.B. Hoon. Cancers 2020, 12, 1692; doi:10.3390/cancers12061692
Disparities in the Occurrence of Late Effects Following Treatment among Adolescent and Young Adult Melanoma Survivors.Alicia A Gingrich 1, Candice A M Sauder 2, Melanie Goldfarb 3, Qian Li 4, Ted Wun 2 4, Theresa H M Keegan 2 4. Cancer Epidemiol Biomarkers Prev (2020). Melanoma is the third most common cancer in the adolescent and young adult (AYA) population. No studies look at the late health effects. Of AYA melanoma survivors, males, those with public/no health insurance, and those living in low SES neighborhoods had a greater likelihood of developing adverse health conditions.